BETA-ADRENOBLOCKERS IN XXI CENTURY: EPOCH END OR IMMORTALITY BEGINNING? A VIEW OF ORDINARY CARDIOLOGIST
https://doi.org/10.20996/1819-6446-2008-4-4-85-89
Abstract
Usage of β-blockers (BB) for treatment of patients with cardiovascular diseases is discussed. Results of the basic clinical trials with BB (LIFE, ASCOT, etc.) are analyzed. The role of sympathetic system in different stages of cardiovascular continuum as well as forecast of BB clinical efficacy is surveyed. Author presents a review of data about selective β1-blocker, metoprolol succinate (Betalok ZОК), in patients with cardiovascular diseases.
About the Author
L. N. Malaj
Medical and Sanitary Unit of Federal Security Service on Khabarovsk Territory, Frunze 123, 55, Khabarovsk, 680000 Russia
Russian Federation
Russian Federation
References
1. Авдеев С.Н., Баймаканова Г.Е. Стратегия ведения кардиологического пациента, страдающего ХОБЛ. Кардио-пульмонологические взаимоотношения. Сердце 2007;6(6):305-9.
2. Бойцов С.А. Закончились ли страсти по -адреноблокаторам? Сердце 2007;5(6):250-3. Затейщиков Д.А., Данковцева Е.Н. -адреноблокаторы в современной кардиологии: метопролола сукци- нат. Кардиология 2007;(8):87-92.
3. Карпов Ю.А. Европейские рекомендации по артериальной гипертонии 2007 г.: β-блокаторы остались в первой пятерке. РМЖ 2007; 15(20):1-6.
4. Маколкин В.И. Значение -адреноблокаторов в лечении артериальной гипертонии. Врач 2007;(1):70-74.
5. Мареев В.Ю. Возможно ли успешное предотвращение внезапной смерти у больных с хронической сердечной недостаточностью и дисфункцией левого желудочка. Препараты или аппараты? Кардиология 2004;(12):4-15.
6. Мареев В.Ю., Арболишвили Г.Н. Проблемы и перспективы -адреноблокаторов в XXI веке: возможные позиции небиволола. Сердце 2007;6(5):240-249.
7. Марцевич С.Ю., Толпыгина С.Н. Бета-адреноблокаторы. В: Беленков Ю.Н., Оганов Р.Г., редакторы. Кардиология. Национальное руководство М.: ГЭОТАР-Медиа; 2007. С. 377–395
8. Терещенко С.Н., Косицына И.В., Джаиани Н.А. Все ли мы знаем об особенностях метопролола в лечении ишемической болезни сердца? Кардиология 2005;(4):98-101.
9. Bangalore S., Messerli H.F., Kostis J.B., Pepine C.J. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007;50 (7):563-72.
10. Bradley H.A., Wiysonge C.S., Volmink J.A. et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006;24 (11):2131- 41.
11. Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003.
12. Dahlof B., Sever P.S., Poulter N.R. et al. Prevention of cardiovascular events with antihypertensive regiment of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906.
13. Hedblad B., Wikstrand J., Janzon L. et al. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001;103:1721-6.
14. Hjalmarson A., Goldstein S., Fagerberg B. et al. Effects of controlledrelease metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA 2000,283:1295-302.
15. Janosi A., Ghali J.K., Herlitz J. et al. Metoprolol СR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERITHF. Am Heart J 2003; 146(4):721-8.
16. Karatzas N.B., Leer J. Metoprolol versus thiazide djuretics in hypertension: morbidity results from the MAPHY Study. Hypertension 1991; 17:579-88.
17. Lindholm L.H., Carlberg B., Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A metaanalysis. Lancet 2005;366:1545-53.
18. Riccio C., Caracciolo M.M., Abrignani M.G. Editorial comment on the British guideline for arterial hypertension, 2006: "Hypertension: management of hypertension in adults in primary care partial update". Monaldi Arch Chest Dis 2006;66(4):238-40.
19. The MERIT-HF investigators. Effect of metoprol CR/XL in chronic heart failure: Metoprol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-7.
20. The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28 (12):1462-536.
21. Wiklund O., Hulthe J., Wikstrand J. et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002;33:572-7.
Review
For citations:
Malaj L.N. BETA-ADRENOBLOCKERS IN XXI CENTURY: EPOCH END OR IMMORTALITY BEGINNING? A VIEW OF ORDINARY CARDIOLOGIST. Rational Pharmacotherapy in Cardiology. 2008;4(4):85-89. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-4-85-89
Views:
599
Email this article 